Full Text of PDF (413k)
Article in Japanese
Abstract
Case Report
A case of immune-related bronchial asthma newly developed following the initiation of nivolumab and ipilimumab combination therapy for malignant pleural mesothelioma, successfully treated with mepolizumab
Tomohiro Onuki Ayami Hirano Sanae Toda Ippei Sakakibara Maiko Matsunami Takeo Kutsuna
Department of Respiratory Medicine, Daido Hospital
ABSTRACT
The patient was a 73-year-old male diagnosed with malignant pleural mesothelioma cT2N0M1 (PUL), cStage IV. Treatment with nivolumab and ipilimumab combination therapy was initiated, resulting in a partial response. Shortly before completion of the third course, the patient developed dry cough and wheezing during nighttime sleep and was diagnosed with bronchial asthma. Despite treatment following severe persistent asthma guidelines, the patient experienced two major attacks in a short period. Mepolizumab therapy was initiated, and symptoms improved. Since there have been reports of an association between treatments targeting PD-1 and PD-L1/PD-L2, and the onset of bronchial asthma, caution is required when administering immune checkpoint inhibitors.
KEYWORDS
Nivolumab Ipilimumab Bronchial asthoma Malignant pleural mesothelioma Mepolizumab
Received 12 Jun 2023 ／ Accepted 10 Aug 2023
AJRS, 12(6): 314-318, 2023
Copyright © The Japanese Respiratory Society All Rights Reserved.